Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Gastrointestinal Stromal Tumors 2Philadelphia Chromosome 1Melanoma 1Digestive System Neoplasms 1Congenital Bone Marrow Failure Syndromes 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 19Vincristine 14Methotrexate 13Prednisone 12Cytarabine 12merphos 11blinatumomab 11Specimen Handling 10Mercaptopurine 10prednylidene 9pegaspargase 9deltacortene 9azathiopurine 9N,N-dicyclohexyl-isoborneol-10-sulfonamide 9Dexamethasone 9Leucovorin 8Doxorubicin 8Biopsy 8dexamethasone acetate 7dexamethasone 21-phosphate 7auricularum 7Etoposide 7Calcium Dobesilate 7Thioguanine 6Spinal Puncture 6Daunorubicin 6Asparaginase 6venetoclax 5fludarabine 5calaspargase pegol 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Burkitt Lymphoma × Imatinib Mesylate × 30 days × Clear all
NCT06124157 2026-06-03

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

National Cancer Institute (NCI)

Phase 2 Recruiting
222 enrolled
Lymphoid

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡